aspirin/omeprazole (Rx)

Brand and Other Names:Yosprala
  • Print

Dosing & Uses


Dosage Forms & Strengths

Aspirin enteric-coated, delayed-release/omeprazole immediate-release

Tablet consists of an enteric-coated delayed-release aspirin core surrounded by an immediate-release omeprazole layer


  • 81mg/40mg
  • 325mg/40mg

Prevention of Cardiovascular and Cerebrovascular Events

Indicated for patients requiring aspirin for secondary prevention of cardiovascular and cerebrovascular events who are at risk of developing aspirin-associated gastric ulcers

1 tablet PO qDay (available in combinations that contain aspirin 81 mg or 325 mg)

Cardiovascular secondary prevention: Generally 81 mg of aspirin has been accepted as an effective dose for secondary cardiovascular prevention

Consider the need for the 325-mg combination as recommended by current clinical practice guidelines

Also see Administration

Dosage Modifications

Renal impairment

  • Mild-to-moderate: No dose reduction required
  • Severe (GFR <10 mL/min): Avoid use owing to the aspirin component (also see Cautions)

Hepatic impairment

  • Avoid use with any degree of hepatic impairment
  • Hepatic impairment increases omeprazole systemic exposure

Dosing Considerations

Limitations of use

  • Aspirin component is delayed release; not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, during acute myocardial infarction, or before percutaneous coronary intervention (PCI)
  • The combination has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin
  • Not interchangeable with the individual components of aspirin and omeprazole

Safety and efficacy not established



Interaction Checker

and aspirin/omeprazole

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            All Interactions Sort By:
             activity indicator 

            Adverse Effects


            325 mg/40 mg (325-mg enteric-coated aspirin alone)

            Gastritis 18% (16%)


            Nausea (3%)

            Diarrhea (3%)

            Gastric polyps (2%)

            Noncardiac chest pain (2%)


            Upper or lower GI bleed

            Small bowel obstruction

            Postmarketing Reports


            • Body as a whole: Fever, hypothermia, thirst Cardiovascular: Dysrhythmias, hypotension, tachycardia
            • Central nervous system: Agitation, cerebral edema, coma, confusion, dizziness, headache, subdural or intracranial hemorrhage, lethargy, seizures
            • Fluid and electrolyte: Dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis
            • Gastrointestinal: Dyspepsia, GI bleeding, ulceration and perforation, nausea, vomiting, transient elevations of hepatic enzymes, hepatitis, Reye syndrome, pancreatitis
            • Hematologic: Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia
            • Hypersensitivity: Acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria
            • Musculoskeletal: Rhabdomyolysis
            • Metabolism: Hypoglycemia (in pediatrics), hyperglycemia
            • Reproductive: Prolonged pregnancy and labor, stillbirths, lower-birth-weight infants, antepartum and postpartum bleeding
            • Respiratory: Hyperpnea, pulmonary edema, tachypnea
            • Special senses: Hearing loss, tinnitus; patients with high-frequency hearing loss may have difficulty perceiving tinnitus; in these patients, tinnitus cannot be used as a clinical indicator of salicylism
            • Urogenital: Interstitial nephritis, papillary necrosis, proteinuria, renal impairment and failure


            • Body as a whole: Hypersensitivity reactions, including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, urticaria, systemic lupus erythematosus, fever, pain, fatigue, malaise
            • Cardiovascular: Chest pain or angina, tachycardia, bradycardia, palpitations, elevated blood pressure, peripheral edema
            • Endocrine: Gynecomastia
            • Gastrointestinal: Pancreatitis (some fatal), anorexia, irritable colon, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, stomatitis, abdominal swelling, dry mouth, microscopic colitis; benign gastric fundic gland polyps have been noted rarely and appear to be reversible when treatment is discontinued; gastroduodenal carcinoids have been reported in patients with Zollinger-Ellison syndrome on long-term treatment with omeprazole (this finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors), fundic gland polyps
            • Hematologic: Agranulocytosis (some fatal), hemolytic anemia, pancytopenia, neutropenia, anemia, thrombocytopenia, leukopenia, leukocytosis
            • Hepatic: Liver disease, including hepatic failure (some fatal), liver necrosis (some fatal), hepatic encephalopathy, hepatocellular disease, cholestatic disease, mixed hepatitis, jaundice, and elevations of liver function tests (ALT, AST, GGT, alkaline phosphatase, and bilirubin)
            • Infections and infestations: Clostridium difficile-associated diarrhea
            • Metabolism and nutritional disorders: Hypoglycemia, hypomagnesemia (with or without hypocalcemia and/or hypokalemia), hyponatremia, weight gain
            • Musculoskeletal: Muscle weakness, myalgia, muscle cramps, joint pain, leg pain, bone fracture
            • Nervous system/psychiatric: Psychiatric and sleep disturbances, including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, apathy, somnolence, anxiety, and dream abnormalities; tremors, paresthesia; vertigo
            • Respiratory: Epistaxis, pharyngeal pain
            • Skin: Severe generalized skin reactions, including toxic epidermal necrolysis (some fatal), Stevens-Johnson syndrome, cutaneous lupus erythematosus and erythema multiforme; photosensitivity; urticaria; rash; skin inflammation; pruritus; petechiae; purpura; alopecia; dry skin; hyperhidrosis
            • Special senses: Tinnitus, taste perversion
            • Ocular: Optic atrophy, anterior ischemic optic neuropathy, optic neuritis, dry eye syndrome, ocular irritation, blurred vision, double vision
            • Urogenital: Interstitial nephritis, hematuria, proteinuria, elevated serum creatinine, microscopic pyuria, urinary tract infection, glycosuria, urinary frequency, testicular pain
            • Acute tubulointerstitial nephritis



            Known allergy to aspirin and other NSAIDs

            Patients with the syndrome of asthma, rhinitis, and nasal polyps; aspirin may cause severe urticaria, angioedema, or bronchospasm

            Known hypersensitivity to aspirin, omeprazole, substituted benzimidazoles, or any of the excipients in the formulation

            Proton pump inhibitors (PPIs) are contraindicated with rilpivirine-containing products

            Not indicated for pediatric patients (safety and efficacy not established); aspirin is contraindicated in children with suspected viral infections, with or without fever, because of the risk of Reye syndrome with concomitant use of aspirin in certain viral illnesses



            • Even low doses of aspirin can inhibit platelet function, leading to an increase in bleeding time; monitor for signs of bleeding
            • Aspirin is associated with serious GI adverse reactions, including inflammation, bleeding ulceration, and perforation of the upper and lower GI tract; other adverse reactions with aspirin include stomach pain, heartburn, nausea, and vomiting
            • Avoid with severe renal failure (GFR <10 mL/min); regular use of aspirin is associated with a dose-dependent increased risk of chronic renal failure; aspirin decreases GFR and renal blood flow, especially with preexisting renal disease
            • Long-term moderate-to high doses of aspirin may result in elevations in serum ALT levels; avoid with any degree of hepatic impairment
            • Aspirin may elevate hepatic enzymes, blood urea nitrogen, and serum creatinine; may cause hyperkalemia, proteinuria, and prolonged bleeding time
            • NSAIDs, including aspirin, may cause premature closure of the fetal ductus arteriosus; avoid use in pregnant women starting at 30 weeks of gestation (see Pregnancy)
            • Drug reaction with eosinophilia and systemic symptoms (DRESS)
              • Drug Reaction reported in patients taking NSAIDs; some of these events have been fatal or life-threatening; DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling
              • Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis; sometimes symptoms of DRESS may resemble an acute viral infection
              • Eosinophilia is often present; because this disorder is variable in its presentation, other organ systems not noted here may be involved
              • Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident; if such signs or symptoms are present, discontinue therapy and evaluate the patient immediately


            • Avoid use in Asian patients with unknown CYP2C19 genotype or those who are known to be poor metabolizers (see Drug Interactions and Pharmacogenomics)
            • Acute tubulointerstitial nephritis (TIN) reported in patients taking PPIs; TIN may occur at any point during PPI therapy; patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions, to non-specific symptoms of decreased renal function (eg, malaise, nausea, anorexia); in reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (eg, fever, rash or arthralgia); discontinue drug and evaluate patients with suspected acute TIN
            • PPIs are possibly associated with increased incidence of C difficile-associated diarrhea (CDAD); consider diagnosis of CDAD for patients taking PPIs who have diarrhea that does not improve
            • Published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, particularly with prolonged (>1 yr), high-dose therapy
            • Daily long-term use (eg, >3 years) may lead to malabsorption or a deficiency of cyanocobalamin
            • Cutaneous lupus erythematosus and systemic lupus erythematosus (SLE) reported with PPIs; SLE typically occurred within days to years after initiating treatment, but some cases occurred days or years after initiating treatment; SLE occurred primarily in patients ranging from young adults to the elderly; majority of patients presented with rash; however, arthralgia and cytopenia were also reported; discontinue therapy and refer patient to appropriate specialist for evaluation; most patients improve with discontinuation of PPI alone in 4 to 12 weeks; serological testing (e.g., ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations
            • Hypomagnesemia may occur with prolonged use (>1 year); adverse effects may result and include tetany, arrhythmias, and seizures; in 25% of cases reviewed, magnesium supplementation alone did not improve low serum magnesium levels and the PPI had to be discontinued
            • Decreased gastric acidity increases serum chromogranin A (CgA) levels and may cause false-positive diagnostic results for neuroendocrine tumors; temporarily discontinue PPIs before assessing CgA levels
            • PPI therapy is associated with increased risk of fundic gland polyp; risk increases with long-term use >1 year; patient may be asymptomatic; problem usually identified incidentally on endoscopy; use shortest duration of therapy appropriate to condition being treated

            Drug interaction overview

            • Also see Interactions section and Drug Interaction Checker
            • Aspirin
              • Because of its ability to inhibit platelet aggregation, low dose aspirin is often used in conjunction with anticoagulants for prevention of thrombotic CV events; closely monitor INR, and for signs and symptoms of bleeding
              • Maintenance doses of aspirin >100 mg reduce ticagrelor effect in preventing thrombotic cardiovascular events; avoid coadministration of ticagrelor with the 325-mg/40-mg tablet strength
              • Counsel patients who consume ≥3 alcoholic drinks/day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin
              • Aspirin may decrease antihypertensive effect of ACE-inhibitors, beta blockers, or diuretics
              • Moderate aspirin doses may increase effect of oral hypoglycemics
            • Omeprazole
              • PPIs are contraindicated with rilpivirine-containing products
              • Omeprazole inhibits hepatic isoenzyme CYP2C19 and may decrease metabolism of drugs that are CYP2C19 substrates (eg, citalopram, cilostazol, phenytoin, diazepam, tacrolimus)
              • Coadministration of clopidogrel with 80-mg omeprazole reduces clopidogrel’s pharmacological activity, even when administered 12 hr apart; avoid coadministration; clopidogrel’s antiplatelet effect is entirely due to an active metabolite; the metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications (eg, omeprazole) that interfere with CYP2C19 activity
              • CYP2C19 or CYP3A4 inducers (eg, St John’s Wort or rifampin) can substantially decrease omeprazole concentrations; avoid coadministration
              • Coadministration of PPIs with methotrexate (primarily at high dose) may elevate and prolong methotrexate serum levels and/or its metabolite, possibly leading to toxicity
              • May increase exposure to digoxin; monitor digoxin concentrations and adjust dose as needed to maintain therapeutic serum concentrations
              • May reduce absorption of drugs that are dependent on gastric pH for absorption (eg, iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole)




            • Use of NSAIDs can cause premature closure of fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment
            • Because of these risks, limit dose and duration of drug combination between about 20 and 30 weeks of gestation, and avoid use at about 30 weeks of gestation and later in pregnancy
            • Use of NSAIDs, including drug combination, at about 30 weeks gestation or later in pregnancy increases risk of premature closure of the fetal ductus arteriosus
            • Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment
            • If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit use to the lowest effective dose and shortest duration possible; if drug combination treatment extends beyond 48 hours, consider monitoring with ultrasound for oligohydramnios; if oligohydramnios occurs, discontinue drug use and follow up according to clinical practice
            • If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit the use to the lowest effective dose and shortest duration possible. If treatment extends beyond 48 hours, consider monitoring with ultrasound for oligohydramnios. If oligohydramnios occurs, discontinue treatment and follow up according to clinical practice
            • Data from observational studies regarding other potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive
            • Based on animal data, prostaglandins have been shown to have important role in endometrial vascular permeability, blastocyst implantation, and decidualization; in animal studies, administration of prostaglandin synthesis inhibitors such as aspirin, resulted in increased pre-and post-implantation loss
            • Prostaglandins also have been shown to have an important role in fetal kidney development; in published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses
            • Reproductive potential
              • Based on mechanism of action, the use of prostaglandin mediated NSAIDs may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women
              • Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation
              • Small studies in women treated with NSAIDs have also demonstrated a reversible delay in ovulation; consider withdrawal of NSAIDs in women who have difficulties conceiving or who are undergoing investigation of infertility


            • Four published epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy with the frequency of abnormalities among infants of women not exposed
            • The number of infants exposed in utero to omeprazole who had any malformation, low birth weight, low Apgar score, or hospitalization was similar to women not exposed in each study
            • Exceptions were the number of infants born with ventricular septal defects and the number of stillborn infants were both slightly higher in the omeprazole-exposed infants than the expected number in this population in 1 study


            Individual components, aspirin and omeprazole, are secreted in human milk

            Limited data describe the presence of aspirin in human milk at relative infant doses of 2.5-10.8% of the maternal weight-adjusted dosage

            Case reports of breastfeeding infants whose mothers were exposed to aspirin during lactation describe adverse reactions, including metabolic acidosis, thrombocytopenia, and hemolysis

            Limited data describe the presence of omeprazole in human milk at a relative infant dose of 0.9% of the maternal weight-adjusted dosage; there are no reports of adverse effects of omeprazole on the breastfed infant

            Because of the potential for serious adverse reactions in the infant, including the potential for aspirin to cause metabolic acidosis, thrombocytopenia, hemolysis, or Reye syndrome, breastfeeding is not recommended during treatment

            Not known if maternal exposure to aspirin during lactation increases risk of Reye’s syndrome in breastfed infants; the direct use of aspirin in infants and children is associated with Reye’s syndrome, even at low plasma levels

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.



            Mechanism of Action

            Aspirin: Inhibits synthesis of thromboxane A2 (prostaglandin derivative) by acetylation of platelet cyclooxygenase, thus inhibiting platelet aggregation

            Omeprazole: Proton pump inhibitor (PPI); binds to H+/K+-exchanging ATPase (proton pump) at the secretory surface of the gastric parietal cells, which results in suppression of basal and stimulated gastric acid secretion


            Take at least 1 hr before meal; food (ie, high-fat meal) significantly prolongs salicylic acid Tmax by 10 hr and reduces omeprazole absorption by 67-84%

            Salicylic acid

            • Intersubject variability range: 17-96%
            • Absorption rate from the GI tract is dependent upon the presence or absence of food, gastric pH (the presence or absence of GI antacids or buffering agents), and other physiologic factors
            • Enteric coated aspirin products are erratically absorbed from the GI tract
            • Peak plasma time: 2.5 hr (81 mg); 4-4.5 hr (325 mg)
            • Peak plasma concentration: 2.6 mcg/mL (81 mg); 2.5 mcg/mL (325 mg)
            • AUC: 3 mcg·hr/mL (81 mg); 2.9 mcg·hr/mL


            • Intersubject variability range: 33-136%
            • Peak plasma time: 0.5 hr
            • Peak plasma concentration: 617-856 ng/mL
            • AUC: 880-1384 mcg·hr/mL


            Salicylic acid

            • Salicylic acid is widely distributed to all tissues and fluids in the body including the CNS, breast milk, and fetal tissues; highest concentrations are found in the plasma, liver, renal cortex, heart, and lungs
            • Protein bound: Concentration dependent; ~90% (concentration >100 mcg/mL); ~75% (concentration >400 mcg/mL)


            • Protein bound: ~95%


            Salicylic acid

            • Aspirin (acetylsalicylic acid) is rapidly hydrolyzed to salicylic acid
            • Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites
            • Metabolism is saturable and total body clearance decreases at higher serum concentrations due to the limited ability of the liver to form both salicyluric acid and phenolic glucuronide


            • Extensively metabolized by CYP; of which the major part of its metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the formation of hydroxyomeprazole, the major metabolite in plasma
            • The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulphone


            Salicylic acid

            • Half-life: 2.4 hr
            • Renal excretion of unchanged drug depends upon urine pH; as urinary pH rises >6.5, the renal clearance of free salicylate increases from 5% >80%
            • Urinary excretion: 10% (salicylic acid); 75% salicyluric acid); 10% (phenolic glucuronide); 5% (acyl glucuronide)


            • Half-life: 1 hr
            • Excretion: 77% urine (as metabolites); remainder in feces


            CYP2C19 poor metabolizers

            • Asians have ~4-fold higher exposure to omeprazole than whites
            • CYP2C19, a polymorphic enzyme, is involved in the metabolism of omeprazole
            • ~15-20% of Asians are CYP2C19 poor metabolizers
            • Tests are available to identify a patient’s CYP2C19 genotype
            • Avoid use in Asian patients with unknown CYP2C19 genotype or those who are known to be poor metabolizers


            Oral Administration

            Take at least 1 hr before a meal

            Swallow whole with liquid; do not split, chew, crush or dissolve


            Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)

            Store in the original container with desiccant and keep the bottle tightly closed to protect from moisture

            Dispense in a tight container if package is subdivided





            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.